371 related articles for article (PubMed ID: 22496222)
1. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.
Lemke CT; Titolo S; von Schwedler U; Goudreau N; Mercier JF; Wardrop E; Faucher AM; Coulombe R; Banik SS; Fader L; Gagnon A; Kawai SH; Rancourt J; Tremblay M; Yoakim C; Simoneau B; Archambault J; Sundquist WI; Mason SW
J Virol; 2012 Jun; 86(12):6643-55. PubMed ID: 22496222
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein.
Wang W; Zhou J; Halambage UD; Jurado KA; Jamin AV; Wang Y; Engelman AN; Aiken C
J Virol; 2017 May; 91(9):. PubMed ID: 28202766
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Maturation: Lessons Learned from Inhibitors.
Kleinpeter AB; Freed EO
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858867
[TBL] [Abstract][Full Text] [Related]
4. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein.
Bartonova V; Igonet S; Sticht J; Glass B; Habermann A; Vaney MC; Sehr P; Lewis J; Rey FA; Kraüsslich HG
J Biol Chem; 2008 Nov; 283(46):32024-33. PubMed ID: 18772135
[TBL] [Abstract][Full Text] [Related]
5. Natural-product-library-based screening for discovery of capsid C-terminal domain targeted HIV-1 inhibitors.
Zhang DW; Luo RH; Xu L; Yang LM; Xu XS; Zheng YT; Luo H
Int J Antimicrob Agents; 2020 Apr; 55(4):105926. PubMed ID: 32092396
[TBL] [Abstract][Full Text] [Related]
6. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography.
Goudreau N; Lemke CT; Faucher AM; Grand-Maître C; Goulet S; Lacoste JE; Rancourt J; Malenfant E; Mercier JF; Titolo S; Mason SW
ACS Chem Biol; 2013 May; 8(5):1074-82. PubMed ID: 23496828
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity.
Bocanegra R; Nevot M; Doménech R; López I; Abián O; Rodríguez-Huete A; Cavasotto CN; Velázquez-Campoy A; Gómez J; Martínez MÁ; Neira JL; Mateu MG
PLoS One; 2011; 6(9):e23877. PubMed ID: 21931621
[TBL] [Abstract][Full Text] [Related]
10. Antiviral inhibition of the HIV-1 capsid protein.
Tang C; Loeliger E; Kinde I; Kyere S; Mayo K; Barklis E; Sun Y; Huang M; Summers MF
J Mol Biol; 2003 Apr; 327(5):1013-20. PubMed ID: 12662926
[TBL] [Abstract][Full Text] [Related]
11. A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
Zhang H; Zhao Q; Bhattacharya S; Waheed AA; Tong X; Hong A; Heck S; Curreli F; Goger M; Cowburn D; Freed EO; Debnath AK
J Mol Biol; 2008 May; 378(3):565-80. PubMed ID: 18374356
[TBL] [Abstract][Full Text] [Related]
12. The Conserved Tyr176/Leu177 Motif in the α-Helix 9 of the Feline Immunodeficiency Virus Capsid Protein Is Critical for Gag Particle Assembly.
Ovejero CA; González SA; Affranchino JL
Viruses; 2019 Sep; 11(9):. PubMed ID: 31487820
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation.
Novikova M; Adams LJ; Fontana J; Gres AT; Balasubramaniam M; Winkler DC; Kudchodkar SB; Soheilian F; Sarafianos SG; Steven AC; Freed EO
mBio; 2018 Oct; 9(5):. PubMed ID: 30327442
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.
Zhang H; Curreli F; Zhang X; Bhattacharya S; Waheed AA; Cooper A; Cowburn D; Freed EO; Debnath AK
Retrovirology; 2011 May; 8():28. PubMed ID: 21539734
[TBL] [Abstract][Full Text] [Related]
15. Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly.
Martin JL; Mendonça LM; Marusinec R; Zuczek J; Angert I; Blower RJ; Mueller JD; Perilla JR; Zhang W; Mansky LM
J Virol; 2018 Jul; 92(14):. PubMed ID: 29695435
[TBL] [Abstract][Full Text] [Related]
16. A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-Terminal domain of capsid.
Zhang DW; Luo RH; Xu L; Yang LM; Xu XS; Bedwell GJ; Engelman AN; Zheng YT; Chang S
Antiviral Res; 2019 Sep; 169():104544. PubMed ID: 31254557
[TBL] [Abstract][Full Text] [Related]
17. Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation.
Joshi A; Nagashima K; Freed EO
J Virol; 2006 Aug; 80(16):7939-51. PubMed ID: 16873251
[TBL] [Abstract][Full Text] [Related]
18. The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly.
Neira JL
FEBS J; 2009 Nov; 276(21):6110-7. PubMed ID: 19825045
[TBL] [Abstract][Full Text] [Related]
19. A peptide inhibitor of HIV-1 assembly in vitro.
Sticht J; Humbert M; Findlow S; Bodem J; Müller B; Dietrich U; Werner J; Kräusslich HG
Nat Struct Mol Biol; 2005 Aug; 12(8):671-7. PubMed ID: 16041387
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization.
Shi J; Zhou J; Shah VB; Aiken C; Whitby K
J Virol; 2011 Jan; 85(1):542-9. PubMed ID: 20962083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
